Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma – PHARMA
Puma Biotechnology Surging
Puma – PHARMA
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
La EMA recomienda no aprobar el fármaco de Puma Biotech
PumaBiotech (@pumabiotech) / Twitter
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Puma – PHARMA
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Pharma (@PumaPharma) / Twitter
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica